Market Research Logo

Pruritus - Market Insight, Epidemiology and Market Forecast - 2027

DelveInsight’s ‘Pruritus in Atopic Dermatitis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Pruritus in Atopic Dermatitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Atopic Dermatitis as well as Pruritus in Atopic Dermatitis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Pruritus in Atopic Dermatitis - Disease Understanding and Treatment Algorithm
The DelveInsight “Pruritus in Atopic Dermatitis” report gives the thorough understanding of the Pruritus in Atopic Dermatitis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pruritus in Atopic Dermatitis in the US, Europe, and Japan.

Pruritus in Atopic Dermatitis Epidemiology
The Pruritus in Atopic Dermatitis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The disease epidemiology covered in the report is segmented by prevalent population of Atopic Dermatitis, Atopic Dermatitis by Severity [mild, moderate & severe], AD by Pruritus burden, AD by Pruritus Severity [Moderate to Severe], Uncontrolled Atopic Dermatitis [Children & Adults] in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the prevalent population of Pruritus in Atopic Dermatitis in 7 major markets was estimated to be 20.58 Million [7MM] in 2016 and, is expected to increase with a significant growth rate from 2016-2027. United States accounts for the highest Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among EU5, Germany has been reported to have the highest prevalent population of pruritus in atopic dermatitis.

Pruritus in Atopic Dermatitis Drug Chapters
This segment of the Pruritus in Atopic Dermatitis report encloses the detailed analysis of marketed drugs and late stage (Phase-III & Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The upcoming therapies for the treatment of Pruritus in Atopic Dermatitis mainly include [Nemolizumab (Galderma Pharma), Tralokinumab (LEO Pharma), Tradipitant (Vanda Pharmaceuticals), ZPL-389 (Novartis), NST-141 (Nippon Shinyaku), etc., have been covered in the report.

Pruritus in Atopic Dermatitis Market Outlook
The Pruritus in Atopic Dermatitis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Pruritus in Atopic Dermatitis was estimated to be USD 1.8 billion in 2016, and is expected to increase with a significant growth rate from 2016-2027.

Pruritus in Atopic Dermatitis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pruritus in Atopic Dermatitis Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Pruritus in Atopic Dermatitis Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Pruritus in Atopic Dermatitis Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Pruritus in Atopic Dermatitis market
• Organize sales and marketing efforts by identifying the best opportunities for Pruritus in Atopic Dermatitis market
• To understand the future market competition in the Pruritus in Atopic Dermatitis market.


1. Report Introduction
2. Pruritus in Atopic Dermatitis Market Overview at a Glance
2.1. Market Share Distribution of Pruritus in Atopic Dermatitis in 2017
2.2. Market Share Distribution of Pruritus in Atopic Dermatitis in 2027
3. Disease Background and Overview
3.1. Etiology
3.2. Risk Factors
3.3. Pathophysiology
3.3.1. Mediators involved in Pathophysiology
3.3.2. Major Mediators for inducing Pruritus in atopic Dermatitis
3.3.3. Emphasis on development of Phosphodiesterase-4 inhibitors
3.3.4. Other Mediators
3.3.5. Potential targets for antipruritic therapy in AD
3.3.6. Triggering factors involved in pathophysiology
3.4. Diagnosis
3.4.1. American Academy of Dermatology Diagnostic Criteria
3.4.2. United Kingdom Working Party Diagnostic criteria
3.4.3. Japanese Dermatological Association Diagnostic Criteria
4. Epidemiology and Patient Population
4.1. Disease Definition
4.2. Population and Forecast Parameters
4.3. Population Methods
4.3.1. Total prevalent cases in the US
4.3.2. EU5
4.3.3. Japan
4.4. Prevalent Population of Atopic Dermatitis in 7MM
4.5. Prevalent Population of Atopic Dermatitis by Severity in 7MM
4.6. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in 7MM
4.6.1. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in the United States
4.6.2. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in Germany
4.6.3. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in France
4.6.4. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in Italy
4.6.5. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in Spain
4.6.6. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in the United Kingdom
4.6.7. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in Japan
4.7. Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases
4.8. Prevalent Cases with Uncontrolled Atopic Dermatitis in 7MM
4.9. Prevalent Cases with Uncontrolled Atopic Dermatitis in Children and Adults in 7MM
5. Treatment Practices
5.1. Treatment Algorithm
5.2. Treatment Goals
5.3. First Line of Treatment
5.4. Second Line of Treatment
6. Treatment Failure
7. Treatment by class
7.1. Topical Therapies
7.2. Systemic therapies
7.3. Approved Drugs for Atopic Dermatitis
8. Emerging Therapies
9. Key Cross Comparision
10. Nemolizumab: Galderma Pharma
10.1. Product Description
10.2. Research and Development
10.3. Product Development Activities
11. Tralokinumab: LEO Pharma
11.1. Product Description
11.2. Research and Development
11.3. Product Development Activities
12. Tradipitant: Vanda Pharmaceuticals
12.1. Product Description
12.2. Research and Development
12.3. Product Development Activities
13. ZPL-389: Novartis
13.1. Product Description
13.2. Research and Development
13.3. Product Development Activities
14. NST-141: Nippon Shinyaku
14.1. Product Description
14.2. Research and Development
14.3. Product Development Activities
15. Serlopitant: Menlo Therapeutics
15.1. Product Description
15.2. Research and Development
15.3. Product Development Activities
16. DS107: DS Biopharma
16.1. Product Description
16.2. Research and Development
16.3. Product Development Activities
17. Asimadoline: Tioga Pharmaceuticals
17.1. Product Description
17.2. Research and Development
17.3. Product Development Activities
18. GSK2894512: GlaxoSmithKline
18.1. Product Description
18.2. Research Development Activities
18.3. Product Development Activities
19. Lebrikizumab: Roche
19.1. Product Description
19.2. Research and Development
20. DMT210: Dermata Therapeutics
20.1. Product Description
20.2. Research and Development
20.3. Product Development Activities
21. SNA-120: Sienna Biopharmaceutical
21.1. Product Description
21.2. Research and Development
21.3. Product Development Activities
22. RVT-501: Roivant Sciences
22.1. Product Description
22.2. Research and Development
22.3. Product Development Activities
23. OPA-15406: Otsuka Pharmaceutical
23.1. Product Description
23.2. Research and Development
23.3. Product Development Activities
24. Current Unmet Need
25. Pruritus in Atopic Dermatitis: Market Analysis
25.1. Market Outlook
25.2. Market size of Atopic Dermatitis in 7MM
25.3. Market size of Pruritus in Atopic Dermatitis in 7MM
26. Pruritus in Atopic Dermatitis: United States Market Outlook
26.1. United States Market size
27. Pruritus in Atopic Dermatitis: EU5 Market Outlook
27.1. Germany Market size
27.2. France Market size
27.3. Italy Market size
27.4. Spain Market size
27.5. United Kingdom Market size
28. Pruritus in Atopic Dermatitis: Japan Market Outlook
28.1. Japan Market size
29. Market Drivers
30. Market Barriers
31. Expert Opinions
32. Views on Current treatment options
33. Views on emerging therapies
34. Appendix
35. Report Methodology
35.1. Sources Used
36. DelveInsight Capabilities
37. Disclaimer
38. About DelveInsight
List of Tables and Figures
Table 1: Mediators of itch in atopic dermatitis by their role in provocation of itch
Table 2: Targets focused by companies
Table 3: Concept of Atopic Dermatitis by Wise and Sulzberger
Table 4: Hanifin and Rajka Diagnostic Criteria
Table 5: American Academy of Dermatology Diagnostic Criteria
Table 6: United Kingdom Working Party diagnostic criteria
Table 7: Japanese Dermatological Association Diagnostic Criteria
Table 8: Total Prevalent Population of Atopic Dermatitis in 7 MM (2016-2027)
Table 9: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2016-2027)
Table 10: Prevalent Population of Atopic Dermatitis by Pruritus Burden in the United States (2016-2027)
Table 11: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Germany (2016-2027)
Table 12: Prevalent Population of Atopic Dermatitis by Pruritus Burden in France (2016-2027)
Table 13: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Italy (2016-2027)
Table 14: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Spain (2016-2027)
Table 15: Prevalent Population of Atopic Dermatitis by Pruritus Burden in UK (2016-2027)
Table 16: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Japan (2016-2027)
Table 17: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2016-2027)
Table 18: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2016-2027)
Table 19:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2016-2027)
Table 20: Reasons for noncompliance with medication
Table 21: Topical corticosteroids
Table 22: Topical Calcineurin Inhibitors (TCIs)
Table 23: Topical Phosphodiesterase Type-4 (PDE4) inhibitors
Table 24: Oral Corticosteroids
Table 25: Biologic medications
Table 26: Systemic Immunomodulating agents
Table 27: Emerging therapies
Table 28: 7 Major Market Size of Atopic Dermatitis in USD Million (2016-2027)
Table 29: 7 Major Market Size of Pruritus in Atopic Dermatitis in USD Million (2016-2027)
Table 30: Market Size of Pruritus in Atopic Dermatitis in United States, USD Millions (2016-2027)
Table 31: Market Size of Pruritus in Atopic Dermatitis in Germany , USD Million (2016-2027)
Table 32: Market Size of Pruritus in Atopic Dermatitis in France, USD Million (2016-2027)
Table 33: Market Size of Pruritus in Atopic Dermatitis in Italy, USD Million (2016-2027)
Table 34: Market Size of Pruritus in Atopic Dermatitis in Spain , USD Million (2016-2027)
Table 35: Market Size of Pruritus in Atopic Dermatitis in United Kingdom, USD Million (2016-2027)
Table 36: Market Size of Pruritus in Atopic Dermatitis in Japan , USD Million (2016-2027)
Figure 1: Risk Factors for Pruritus in Atopic Dermatitis
Figure 2: Pathophysiology of Pruritus in Atopic Dermatitis
Figure 3: Mediators involved in Pathophysiology of Pruritus in Atopic Dermatitis
Figure 4: Mediators with their mechanism of action in inducing Pruritus in atopic Dermatitis
Figure 5: Triggering factors involved in pathophysiology of Pruritus in Atopic Dermatitis
Figure 6: Total Prevalent Population of Atopic Dermatitis in 7 MM (2016-2027)
Figure 7: Total Prevalent Population of Atopic Dermatitis by Severity in 7 MM (2016-2027)
Figure 8: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2016-2027)
Figure 9: Prevalent Population of Atopic Dermatitis by Pruritus Burden in the United States (2016-2027)
Figure 10: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Germany (2016-2027)
Figure 11: Prevalent Population of Atopic Dermatitis by Pruritus Burden in France (2016-2027)
Figure 12: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Italy (2016-2027)
Figure 13: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Spain (2016-2027)
Figure 14: Prevalent Population of Atopic Dermatitis by Pruritus Burden in the UK (2016-2027)
Figure 15: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Japan (2016-2027)
Figure 16: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2016-2027)
Figure 17: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2016-2027)
Figure 18: Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2016-2027)
Figure 19: General Treatment for Pruritus in Atopic Dermatitis
Figure 20: First Line of treatment for Pruritus in Atopic Dermatitis
Figure 21: Second Line of treatment for Pruritus in Atopic Dermatitis
Figure 22: Current Unmet Need for Pruritus in Atopic Dermatitis
Figure 23: 7 Major Market Size of Atopic Dermatitis in USD Million (2016-2027)
Figure 24: 7 Major Market Size of Pruritus in Atopic Dermatitis in USD Million (2016-2027)
Figure 25: Market Size of Pruritus in Atopic Dermatitis in United States, USD Millions (2016-2027)
Figure 26: Market Size of Pruritus in Atopic Dermatitis in Germany , USD Million (2016-2027)
Figure 27: Market Size of Pruritus in Atopic Dermatitis in France, USD Million (2016-2027)
Figure 28: Market Size of Pruritus in Atopic Dermatitis in Italy, USD Million (2016-2027)
Figure 29: Market Size of Pruritus in Atopic Dermatitis in Spain, USD Million (2016-2027)
Figure 30: Market Size of Pruritus in Atopic Dermatitis in United Kingdom , USD Million (2016-2027)
Figure 31:Market Size of Pruritus in Atopic Dermatitis in Japan , USD Million (2016-2027)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report